Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials

Background: As immune checkpoint inhibitors (ICIs) transition to the forefront of cancer treatment, a better understanding of immune related adverse events (IRAEs) is essential to promote safe clinical practice. Dermatologic adverse events are the most common IRAEs and can lead to drug withdrawal an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Yang, Zhang, Huiyun, Weygant, Nathaniel, Yao, Jiannan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383780/
https://www.ncbi.nlm.nih.gov/pubmed/34447305
http://dx.doi.org/10.3389/fphar.2021.640099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383780/
https://www.ncbi.nlm.nih.gov/pubmed/34447305
http://dx.doi.org/10.3389/fphar.2021.640099

Ejemplares similares